Search Results for: drug patents
FDA approves 45 new drugs. 47 percent qualify for 50 percent Orphan Drug tax credit
In calendar year 2015, FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel drugs, approved as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs). This is a large number of approvals.
WIPO SCP23 – 1 December 2015 – Statement of Knowledge Ecology International on Patents and Health
1 December 2015
World Intellectual Property Organization (WIPO) Standing Committee on the Law of Patents (SCP 23)
KEI Statement on Patents and Health
Thank you Madame Chair
KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
November 23, 2015
FYI: Contact: Andrew Goldman (andrew.goldman@keionline.org) or Zack Struver (zack.struver@keionline.org)
Knowledge Ecology International (KEI) notes the successful conclusion of negotiations between Bristol-Myers Squibb (BMS) and the Medicines Patent Pool (MPP) for a royalty-free license and technology transfer agreement on daclatasvir (DCV), an important new medicine for the treatment of the hepatitis C virus (HCV), and offers comments on the agreement.
Economist Bhaven Sampat presents research on role of government funding in drug development
WTO Decision on Least Developed Country (LDC) Drug Patent Waiver
For Immediate Release
3 November 2015
Contact: Zack Struver, +1 (202) 332-2670 or zack.struver@keionline.org
Geneva — The World Trade Organization is poised to announce this Friday its approval of a limited 17-year extension of a 2001 waiver of obligations in the TRIPS Agreement, set to expire at the end of this year, the terms of which exempt Least Developed Countries (LDCs) from requirements to grant patents or related intellectual property rights on pharmaceutical products.
Contrast in privilege: US officials working to block WTO LDC drug patent waiver, and people affected by policy
On the left, the people in the Obama Administration trying to block a permanent waiver of WTO drug patent obligations for Least Developed Countries (as defined by the UN). On the right, some people living in least developed countries.
 Ambassador Michael Forman. Head of USTR. Alma maters: Princeton, Oxford and Harvard Law. Formerly ran a hedge fund for Citibank. Continue Reading US, AU and CA try to block WTO LDC drug patent waiver because PhRMA’s not happy enough with the TPPMembers of the World Trade Organization (WTO) meet this week in Geneva (15 October 2015 – 16 October 2015) to decide if the poorest countries on earth are exempt from WTO rules for pharmaceutical patents. The WTO’s TRIPS Council is expected to make a decision in respect of the request of the LDC Group’s request for indefinite exemption from TRIPS obligations on pharmaceutical patents. Continue Reading Press Release: Coalition for Affordable T-DM1 Asks UK Government to grant compulsory licenses on Roche breast cancer drugPress Release: Coalition for Affordable T-DM1 Asks the UK Government to Employ Crown Use Authority to Lower Price of Expensive Cancer Drug sold by Roche CONTACT: Diarmaid McDonald Susannah Markandya Zack Struver WIPO SCP 22: Written Statement of Knowledge Ecology International on Patents and Health28 July 2015 |